Fortress Biotech (FBIO) Buy Rating Reaffirmed at Cantor Fitzgerald


Fortress Biotech (NASDAQ:FBIO – Get Appraisal)The stock had its “buy” rating reissued by Cantor Fitzgerald stock research analysts in a report released on Friday, TipRanks reports. They currently have a price target of $6.00 on shares of the biopharmaceutical company.

FBIO has been the subject of a number of other reports. StockNews.com downgraded Fortress Biotech from a “hold” rating to a “sell” rating in a report released Wednesday. Zacks Investment Research upgraded Fortress Biotech from a “strong sell” rating to a “hold” rating in a research note on Friday. TheStreet downgraded Fortress Biotech from a “c-” rating to a “d+” rating in a Monday, February 14 research note. Finally, Roth Capital reaffirmed a “buy” rating on Fortress Biotech shares in a Tuesday, March 29 research note. One research analyst rated the stock with a sell rating, another has issued a hold rating and five have assigned the stock a buy rating. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $9.50.

FBIO traded as low as $0.06 in Friday’s midday session, reaching $0.86. 695,679 shares of the company were traded, against an average volume of 677,202. The company has a debt ratio of 0.21, a quick ratio of 3.33 and a current ratio of 3.43. The company’s fifty-day moving average price is $1.21 and its 200-day moving average price is $2.03. The company has a market capitalization of $91.92 million, a price-earnings ratio of -1.00 and a beta of 2.27. Fortress Biotech has a 1-year low of $0.79 and a 1-year high of $4.49.

Fortress Biotech (NASDAQ:FBIO – Get Rating) last released its quarterly earnings data on Thursday, May 12. The biopharmaceutical company reported ($0.18) EPS for the quarter, beating analyst consensus estimates of ($0.28) by $0.10. Fortress Biotech had a negative return on equity of 31.30% and a negative net margin of 88.31%. In the same quarter last year, the company posted ($0.11) earnings per share. As a group, sell-side analysts expect Fortress Biotech to post -0.93 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of FBIO. Morgan Stanley increased its stake in Fortress Biotech by 768.2% in the second quarter. Morgan Stanley now owns 266,945 shares of the biopharmaceutical company valued at $953,000 after buying an additional 236,198 shares in the last quarter. Bank of America Corp DE increased its stake in Fortress Biotech by 102.1% in the second quarter. Bank of America Corp DE now owns 106,334 shares of the biopharmaceutical company valued at $379,000 after buying an additional 53,730 shares in the last quarter. Millennium Management LLC increased its stake in Fortress Biotech by 73.3% in the second quarter. Millennium Management LLC now owns 34,621 shares of the biopharmaceutical company valued at $124,000 after purchasing an additional 14,646 shares in the last quarter. Wells Fargo & Company MN increased its stake in Fortress Biotech by 108.4% in the second quarter. Wells Fargo & Company MN now owns 151,972 shares of the biopharmaceutical company valued at $543,000 after purchasing an additional 79,049 shares last quarter. Finally, SG Americas Securities LLC acquired a new position in Fortress Biotech in the third quarter worth approximately $79,000. Institutional investors and hedge funds hold 30.92% of the company’s shares.

About Fortress Biotech (Get a rating)

Fortress Biotech, Inc., a biopharmaceutical company, develops and markets pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of moderate to severe non-nodular acne vulgaris; Targadox for severe acne; Exelderm cream for symptoms of ringworm and jock itch; Ceracade for dry skin; Luxamend for dressing and treating wounds; and Accutane capsules for severe recalcitrant nodular acne.

See also



Get news and reviews for Fortress Biotech Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fortress Biotech and related companies with MarketBeat.com’s free daily email newsletter.

About Sally Dominguez

Check Also

“My acne was so bad that I stopped having sex – but now I’ve found a natural cure”

Mandy Nazé, 29, says her face, forehead, chest, neck and back were badly affected and …